At the heart of our strategy is the establishment of high-efficiency cannabis cultivation facilities in regions that offer low-cost product inputs, favourable climates, political stability, and the capacity for wholesale exports to high-margin markets. White Sheep’s leadership and operations teams have proven track records in designing, building, and operating fully compliant cannabis facilities which provide patients with a consistent and safe supply of cannabis.

Cultivation, Extraction & Processing

White Sheep’s core assets include land and operating licenses in jurisdictions which are ideally suited for the commercial cultivation of medicinal cannabis.  These proprietary facilities will be among the largest in the world and will provide legal markets around the world with a large scale source of high quality cannabis.


White Sheep has secured 10 hectares of land in Lesotho, Africa, and a definitive vertically integrated license to cultivate, extract, package and export cannabinoid rich oils in Lesotho, Africa.  The facility is under construction and, once completed, will span 1,000,000 sq.ft and produce an expected yield of approx 194,000 kgs.  Lesotho is known for benevolent mountainous conditions that are ideally suited for controlled greenhouse operations such as ours:  high altitude, low humidity, and sunny climate, and fresh mountain water which is untainted by pesticides or pathogens. Lesotho is a politically stable constitutional monarchy led by a pro-medical cannabis government and there is a stable and experienced work force that is already accustomed to adhering to cGMP standards.

White Sheep also has majority interest in a vertically integrated production license (pending) in Eswatini (formerly Swaziland), subject to implementation of the country’s medical cannabis regulatory regime. This facility will be 3.5-million square feet and able to produce 437,500 kgs of medicinal cannabis.

Read our press release
View the Gallery


White Sheep recognizes that investments must be made into technology and innovation to attain and maintain the lead position as the global cannabis supplier of choice.  As such, we have made several investments in promising areas that may result in industry disrupting technologies.

Biomedican is a biotech firm based in the Bay Area that is concerned with the biosynthetic creation of cannabinoids using yeast instead of plants.  The team is led by an experienced entrepreneur, with a PhD in molecular biology, who had a successful exit from his bioinformatics start-up.  Biomedican has created a novel approach to the biosynthesis of cannabinoids and has marshaled experts across the globe, leaders in their respective fields, to ensure the speed and success of these efforts.

Ancillary Investments

White Sheep also holds ancillary investments in non-plant touching ventures.

Altopa, Inc., based in Raleigh NC, is commercializing a countertop delivery device for compounding and dispensing botanical oils at pharmaceutical level accuracy, on-demand, for accurate and consistent dosing and effect.

The #1 choice for licensed producers in Canada, Ample Organics is a comprehensive business platform designed for the cannabis industry, one software solution with tracking, reporting, data, sales, support and security functions.  Ample’s cannabis-centric retail solution leverages industry standard point of sale hardware.  We are proud to have been a part of the company’s trajectory through to its announced acquisition by Akerna.

Cannabis Big Data (CBD) provides turn-key business intelligence dashboards, reports & insights for dispensaries, grows, MIPs and investors. CBD integrates with your data sources (POS, Seed to Sale, Accounting, etc.) then publish critical business management reports to identify areas where you can save on costs or earn more revenue.